Max Mendez-Lopez
Overview
Explore the profile of Max Mendez-Lopez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Besse A, Kraus M, Mendez-Lopez M, Maurits E, Overkleeft H, Driessen C, et al.
Cells
. 2022 Mar;
11(5).
PMID: 35269460
Targeting proteasome with proteasome inhibitors (PIs) is an approved treatment strategy in multiple myeloma that has also been explored pre-clinically and clinically in other hematological malignancies. The approved PIs target...
2.
Yurchenko A, Pop O, Ighilahriz M, Padioleau I, Rajabi F, Sharpe H, et al.
Clin Cancer Res
. 2022 Jan;
28(7):1422-1432.
PMID: 35078858
Purpose: Vismodegib is approved for the treatment of locally advanced basal cell carcinoma (laBCC), but some cases demonstrate intrinsic resistance (IR) to the drug. We sought to assess the frequency...
3.
Mendez-Lopez M, Sutter T, Driessen C, Besse L
Clin Adv Hematol Oncol
. 2019 Dec;
17(11):615-623.
PMID: 31851164
Outcomes in multiple myeloma (MM) patients have improved in recent years owing to the introduction of new drugs. Among them, proteasome inhibitors and immunomodulatory imide drugs have become central in...
4.
Besse L, Besse A, Mendez-Lopez M, Vasickova K, Sedlackova M, Vanhara P, et al.
Haematologica
. 2019 Feb;
104(9):e415-e419.
PMID: 30792209
No abstract available.
5.
Besse A, Besse L, Kraus M, Mendez-Lopez M, Bader J, Xin B, et al.
Cell Chem Biol
. 2019 Jan;
26(3):340-351.e3.
PMID: 30612952
Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified as rate-limiting and is a...